Clinical Trials Logo

Hypomethylating Agents clinical trials

View clinical trials related to Hypomethylating Agents.

Filter by:
  • None
  • Page 1

NCT ID: NCT04999943 Recruiting - Clinical trials for Myelodysplastic Syndromes

Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome

eDC-MDS
Start date: July 1, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to optimize the traditional treatment scheme and explore the cure scheme for the elderly by combining the existing mature treatment technology. The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of MDS patients.

NCT ID: NCT04454580 Recruiting - Clinical trials for Acute Myeloid Leukemia, Adult

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Start date: August 1, 2020
Phase:
Study type: Observational

This is a retrospective, observational, monocentric study to evaluate the efficacy and safety of the combination of an hypomethylating agent with venetoclax newly diagnosed patients with acute myeloid leukemia ineligible for intensive chemotherapy